Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity

Although the sodium channel blocker, mexiletine, is the first choice drug in myotonia, some myotonic patients remain unsatisfied due to contraindications, lack of tolerability, or incomplete response. More therapeutic options are thus needed for myotonic patients, which require clinical trials based...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Neuropharmacology
Главные авторы: De Bellis, Michela, Carbonara, Roberta, Roussel, Julien, Farinato, Alessandro, Massari, Ada, Pierno, Sabata, Muraglia, Marilena, Corbo, Filomena, Franchini, Carlo, Carratù, Maria Rosaria, De Luca, Annamaria, Conte Camerino, Diana, Desaphy, Jean-François
Формат: Artigo
Язык:Inglês
Опубликовано: Pergamon Press 2017
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5154332/
https://ncbi.nlm.nih.gov/pubmed/27743929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neuropharm.2016.10.013
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы